GFR-话题@MedSci

#GFR#

483篇内容 | 2613人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534380, encodeId=57eb1534380cb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：达克替尼一线用于EGFR突变NSCLC患者，生存期达34.1个月（ARCHER 1050研究）, objectType=article, longId=141439, objectId=d96a141439e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d96a141439e2, replyNumber=0, likeNumber=58, createdTime=2018-06-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d96a141439e2, moduleTitle=JCO：达克替尼一线用于EGFR突变NSCLC患者，生存期达34.1个月（ARCHER 1050研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d96a141439e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534379, encodeId=82d615343e9b9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, objectType=article, longId=139220, objectId=46ac139220d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ac139220d5, replyNumber=0, likeNumber=57, createdTime=2018-05-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ac139220d5, moduleTitle=Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ac139220d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534378, encodeId=b8ac15343e80e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CHEM：24小时内肌酸酐，半胱氨酸蛋白酶抑制剂C和eGFR的生物学变异, objectType=article, longId=138828, objectId=1d7c13882881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d7c13882881, replyNumber=0, likeNumber=89, createdTime=2018-05-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d7c13882881, moduleTitle=CLIN CHEM：24小时内肌酸酐，半胱氨酸蛋白酶抑制剂C和eGFR的生物学变异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d7c13882881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534377, encodeId=a2e815343e773, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=刘喆教授：肺癌脑实质转移患者，脑脊液EGFR突变检测可用于临床, objectType=article, longId=135201, objectId=7480135201ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7480135201ac, replyNumber=0, likeNumber=115, createdTime=2018-04-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7480135201ac, moduleTitle=刘喆教授：肺癌脑实质转移患者，脑脊液EGFR突变检测可用于临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7480135201ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534376, encodeId=0bcd15343e67b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, objectType=article, longId=134084, objectId=2a11134084c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a11134084c4, replyNumber=0, likeNumber=103, createdTime=2018-04-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a11134084c4, moduleTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a11134084c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534375, encodeId=b22315343e5d4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：CAR T细胞治疗EGFR阳性晚期胆道癌患者, objectType=article, longId=133045, objectId=bbcc13304584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbcc13304584, replyNumber=0, likeNumber=89, createdTime=2018-03-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbcc13304584, moduleTitle=CLIN CANCER RES：CAR T细胞治疗EGFR阳性晚期胆道癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbcc13304584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534374, encodeId=f22f15343e449, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：EGFR/ALK阳性的NSCLC多线靶向治疗后仍可用免疫治疗？, objectType=article, longId=132965, objectId=c7691329653a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7691329653a, replyNumber=0, likeNumber=120, createdTime=2018-03-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7691329653a, moduleTitle=Lancet Oncol：EGFR/ALK阳性的NSCLC多线靶向治疗后仍可用免疫治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7691329653a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534373, encodeId=733415343e328, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：刷新认知! EGFR/ALK基因驱动的NSCLC仍可用免疫治疗！, objectType=article, longId=132778, objectId=9736132e7851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9736132e7851, replyNumber=0, likeNumber=89, createdTime=2018-03-19, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9736132e7851, moduleTitle=Lancet Oncol：刷新认知! EGFR/ALK基因驱动的NSCLC仍可用免疫治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9736132e7851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534372, encodeId=ede415343e29c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Stem cells：Sca-1+/PDGFRa-细胞是成人中胚层祖细胞，与动脉粥样硬化过程的血管钙化相关, objectType=article, longId=132075, objectId=5fec1320e52c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fec1320e52c, replyNumber=0, likeNumber=49, createdTime=2018-03-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fec1320e52c, moduleTitle=Stem cells：Sca-1+/PDGFRa-细胞是成人中胚层祖细胞，与动脉粥样硬化过程的血管钙化相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fec1320e52c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534371, encodeId=42d115343e1ac, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell Microbiol：牙龈卟啉单胞菌与EGFR信号通路在CXCL14调控中的相互作用, objectType=article, longId=131838, objectId=55c5131838c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55c5131838c6, replyNumber=0, likeNumber=15, createdTime=2018-03-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55c5131838c6, moduleTitle=Cell Microbiol：牙龈卟啉单胞菌与EGFR信号通路在CXCL14调控中的相互作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55c5131838c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534370, encodeId=14bd15343e01d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：Olaratumab通过抑制PDGFRα发挥抗肿瘤作用, objectType=article, longId=130866, objectId=4d35130866ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d35130866ec, replyNumber=0, likeNumber=75, createdTime=2018-03-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d35130866ec, moduleTitle=CLIN CANCER RES：Olaratumab通过抑制PDGFRα发挥抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d35130866ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534369, encodeId=ce9a153436947, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：高T790M 与EGFR突变比值与奥希替尼疗效相关, objectType=article, longId=129883, objectId=8c7d1298839d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7d1298839d, replyNumber=0, likeNumber=60, createdTime=2018-02-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7d1298839d, moduleTitle=Lung Cancer：高T790M 与EGFR突变比值与奥希替尼疗效相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c7d1298839d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534368, encodeId=12991534368cd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：Tivantinib+厄洛替尼一线治疗EGFR突变NSCLC： MARQUEE研究亚组分析, objectType=article, longId=129878, objectId=0b251298e8ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b251298e8ac, replyNumber=0, likeNumber=71, createdTime=2018-02-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b251298e8ac, moduleTitle=J Thorac Oncol：Tivantinib+厄洛替尼一线治疗EGFR突变NSCLC： MARQUEE研究亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b251298e8ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534367, encodeId=4fb6153436e9e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：阿法替尼联合贝伐珠单抗治疗EGFR突变NSCLC的Ⅰ期研究, objectType=article, longId=129855, objectId=efd412985541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efd412985541, replyNumber=0, likeNumber=72, createdTime=2018-02-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efd412985541, moduleTitle=Lung Cancer：阿法替尼联合贝伐珠单抗治疗EGFR突变NSCLC的Ⅰ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efd412985541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534366, encodeId=f4c61534366c7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Blood：在Ph样急性淋巴细胞白血病中发现一新的与酪氨酸激酶抑制剂耐药性直接相关的PDGFRB突变, objectType=article, longId=129567, objectId=985a12956e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=985a12956e3b, replyNumber=0, likeNumber=59, createdTime=2018-02-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=985a12956e3b, moduleTitle=Blood：在Ph样急性淋巴细胞白血病中发现一新的与酪氨酸激酶抑制剂耐药性直接相关的PDGFRB突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=985a12956e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534365, encodeId=9d38153436594, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=程颖教授：针对EGFR突变肺癌患者的更精准治疗, objectType=article, longId=127537, objectId=c99d12e537a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c99d12e537a5, replyNumber=0, likeNumber=85, createdTime=2018-01-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c99d12e537a5, moduleTitle=程颖教授：针对EGFR突变肺癌患者的更精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c99d12e537a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534364, encodeId=368915343641e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JACC：EGFR抑制剂是治疗动脉粥样硬化潜在的新靶点, objectType=article, longId=126943, objectId=9f0d126943e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0d126943e9, replyNumber=0, likeNumber=73, createdTime=2018-01-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0d126943e9, moduleTitle=JACC：EGFR抑制剂是治疗动脉粥样硬化潜在的新靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0d126943e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534363, encodeId=66c01534363f3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著, objectType=article, longId=126225, objectId=afde12622574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afde12622574, replyNumber=0, likeNumber=65, createdTime=2018-01-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afde12622574, moduleTitle=NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afde12622574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534362, encodeId=5696153436226, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用, objectType=article, longId=125226, objectId=585212522636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=585212522636, replyNumber=0, likeNumber=0, createdTime=2018-01-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=585212522636, moduleTitle=EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=585212522636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534361, encodeId=4a5c1534361f0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, objectType=article, longId=124734, objectId=05dd124e34e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05dd124e34e0, replyNumber=0, likeNumber=109, createdTime=2017-12-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05dd124e34e0, moduleTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05dd124e34e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：达克替尼一线用于EGFR突变NSCLC患者，生存期达34.1个月（ARCHER 1050研究）

2018-06-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Brit J Cancer：转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究

2018-05-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CHEM：24小时内肌酸酐，半胱氨酸蛋白酶抑制剂C和eGFR的生物学变异

2018-05-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

刘喆教授：肺癌脑实质转移患者，脑脊液EGFR突变检测可用于临床

2018-04-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效

2018-04-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：CAR T细胞治疗EGFR阳性晚期胆道癌患者

2018-03-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：EGFR/ALK阳性的NSCLC多线靶向治疗后仍可用免疫治疗？

2018-03-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：刷新认知! EGFR/ALK基因驱动的NSCLC仍可用免疫治疗！

2018-03-19

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Stem cells：Sca-1+/PDGFRa-细胞是成人中胚层祖细胞，与动脉粥样硬化过程的血管钙化相关

2018-03-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell Microbiol：牙龈卟啉单胞菌与EGFR信号通路在CXCL14调控中的相互作用

2018-03-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：Olaratumab通过抑制PDGFRα发挥抗肿瘤作用

2018-03-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：高T790M 与EGFR突变比值与奥希替尼疗效相关

2018-02-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：Tivantinib+厄洛替尼一线治疗EGFR突变NSCLC： MARQUEE研究亚组分析

2018-02-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：阿法替尼联合贝伐珠单抗治疗EGFR突变NSCLC的Ⅰ期研究

2018-02-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Blood：在Ph样急性淋巴细胞白血病中发现一新的与酪氨酸激酶抑制剂耐药性直接相关的PDGFRB突变

2018-02-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

程颖教授：针对EGFR突变肺癌患者的更精准治疗

2018-01-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JACC：EGFR抑制剂是治疗动脉粥样硬化潜在的新靶点

2018-01-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

NEJM：奥斯替尼一线治疗EGFR突变阳性非小细胞肺癌疗效显著

2018-01-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用

2018-01-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI

2017-12-28

科室
- - 订阅+
  - 更多科室
工具
服务